Clindesse(TM) contains mineral oil that may weaken latex or rubber
products such as condoms or vaginal contraceptive diaphragms.

spirochetal abscesses

Osel Initiates Two Phase II Trials for LACTIN-V

, the
Bacterio -Therapeutics company, announced the initiation of two Phase II
clinical trials of LACTIN-V, one for the treatment of recurrent urinary tract
infection (RUTI), and a second for recurrent bacterial vaginosis (RBV).
LACTIN-V, a vaginal capsule containing a natural human bacterial organism,
will be studied in a total of eight centers for RUTI and for RBV under the
clinical direction of Lynn Conrad , MD, University of Tennessee Health Science
Center, Memphis (RUTI), and Benson Horowitz, MD, University of Connecticut
(RBV). Up to 33% of
women with UTIs develop recurrent infections (>2 per year) . Thus, there is
significant interest amongst women who suffer from RUTI for novel
non-antibiotic therapies.

About Osel
Osel, Inc. Clindesse(TM) (clindamycin phosphate 2% vaginal cream) is
the first single-dose treatment for bacterial vaginosis (BV), the most common
form of vaginitis. The most frequently reported adverse events were vaginosis fungal
(14.

parasitologists trachoma

We believe the convenience of these products will be compelling to both
physicians and their patients as we continue to expand our international
presence with our latest partner, Vitaflo. Such
statements may be identified by the use of words like "plans", "expect",
"aim", "believe", "projects", "anticipate ", "commit", "intend", "estimate",
"will", "should", "could" and other expressions that indicate future events
and trends.

mycologists trachoma

For further information about Vitaflo Scandinavia AB, please visit the
Company's corporate website at http://www.

electonic mycobacterial

, and an equal number in Europe.
This latest agreement adds Sweden, Denmark, Norway, Finland and Iceland,
to the list of more than 50 markets worldwide in which KV has licenses in
place for the sale of Gynazole-1(R), and it's the fourth international
licensing announcement for the more recently introduced Clindesse(TM). Therefore, the
use of such barrier contraceptives is not recommended concurrently or for 5
days following treatment with Clindesse(TM).

abscesses parasitologists

Contact: Ralph Levy President, Osel Inc.
Under the terms of the agreement , KV will receive licensing fees and
manufacturing revenues for both products. Hermelin, Vice Chairman of the Board and CEO of KV stated,
"Gynazole-1(R) and Clindesse(TM) offer significant innovation for patients.
Gynazole-1(R) is contraindicated in patients with a history of
hypersensitivity to any of the components in the product.6% of the patients discontinued therapy due to adverse
events .1%), vulvovaginal pruritus (3.

prion influenza

"We are moving ahead with our business plan to develop products
utilizing naturally occurring mucosal bacteria.

Safe Harbor
The information in this release may contain various forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include
assumptions concerning KV's operations, future results and prospects.

candidiasis electonic

, Osel, Inc.U.
Marc S.

Clindesse(TM ) (clindamycin phosphate) Vaginal Cream, 2%
Clindesse(TM) is contraindicated in individuals with a history of
hypersensitivity to clindamycin, lincomycin, or any of the components of this
vaginal cream, and in individuals with a history of regional enteritis,
ulcerative colitis, or a history of "antibioitic-associated" colitis.

mycobacterial infections

LACTIN-V
contains a natural human bacterium, Lactobacillus crispatus , which has been
carefully selected based upon detailed scientific findings that demonstrate
its unique ability to colonize the vaginal mucosa and to secrete substances
that inhibit the growth of microbial pathogens.
Such factors include (but are not limited to) the following: (1) changes
in the current and future business environment, including interest rates and
capital and consumer spending; (2) the difficulty of predicting FDA approvals,
including timing, and that any period of exclusivity may not be realized; (3)
acceptance and demand for new pharmaceutical products; (4) the impact of
competitive products and pricing; (5) new product development and launch
including but not limited to the possibility that any product launch may be
delayed or that product acceptance may be less than anticipated; (6) reliance
on key strategic alliances; (7) the availability of raw materials; (8) the
regulatory environment; (9) fluctuations in operating results; (10) the
difficulty of predicting international regulatory approvals, including
timing; (11) the difficulty of predicting the pattern of inventory movements
by the Company's customers; (12) the impact of competitive response to the
Company's sales, marketing and strategic efforts; (13) risks that the Company
may not ultimately prevail in litigation; and (14) the risks detailed from
time to time in the Company's filings with the Securities and Exchange
Commission.

Also see specific diseases within the alphabetical listings .

influenza infectious

S. 206
Cell : 415-699-0135
Email: rlevy@oselinc.
Vitaflo will market KV's proprietary Gynazole-1(R) product in the E. The turnover has
more than doubled each year since 2000.

Communicable/infectious diseases sites.

h5n1 prion

under
the trade name Gynafem(TM).
Gynazole-1(R ) (butocanzole nitrate 2% vaginal cream) is KV's proprietary
prescription one-dose vaginal cream for the treatment of yeast infections
caused by Candida. The outstanding success of both
these products in the U. is a good indicator of their untapped potential in
international arenas as they are promoted by our outstanding partners. Therefore, it is
important to consider this diagnosis in patients who present with diarrhea
subsequent to the administration of clindamycin, even though there is minimal
systemic absorption of clindamycin from the vagina with administration of
Clindesse(TM) cream .
Strategically Vitaflo is organized in four Geografic areas that include
pharmaceuticals (Female Care, Dermatology, Gastro, Medical Odontology, Medical
Nutrition, Pediatrics, and Vaccines).

niaid zoonoses

S.
For further information about KV Pharmaceutical Company, please visit the
Company's corporate website at http://www.

niaid spirochetal

Osel's first product, LACTIN-V, is directed at recurrent urinary tract
infections (RUTI), and recurrent bacterial vaginosis (RBV)."

Additional Safety Information about Gynazole-1(R) and Clindesse(TM):

Gynazole-1(R) (butoconazole nitrate) Vaginal Cream 2%
Gynazole-1(R) is indicated for the local treatment of vulvovaginal
candidasis. If clinical symptoms persist, tests should be repeated to rule out
other pathogens, to conform original diagnosis , and to rule out other
conditions that may predispose a patient to recurrent vaginal fungal
infections .

h5n1 electonic

KV Adds To Its Prestigious International Licensing Partnerships For
Gynazole -1(R) and Clindesse(TM)

ST.

abscesses mycologists

SANTA CLARA, Calif. During this time period, condoms
may not be reliable for preventing pregnancy or for protecting against
transmission of HIV or other sexually transmitted diseases.vitaflo.
All forward-looking statements are based on current expectations and are
subject to risk and uncertainties. We are under no
obligation to update any of the forward -looking statements after the date of
this report.

rickettsial zoonoses

Bacterial vaginosis (BV) afflicts over 16 million
women every year worldwide, and is the most common reason that women seek
medical help, after vaginal yeast infections. Both Gynazole-1(R) and Clindesse(TM) are the fastest
growing products in branded market share for their categories, currently at
approximately 30% and 17% of new prescriptions , respectively.

cdsc pneumonia

and Europe," said Osel president, Ralph Levy. The Company markets its technology distinguished products through
ETHEX Corporation, a national leader in pharmaceuticals that compete with
branded products, and Ther-Rx Corporation, its emerging branded drug
subsidiary.kvpharmaceutical.
This discussion is by no means exhaustive, but is designed to highlight
important factors that may impact the Company's outlook.

influenza infectious

Both diseases
result from deficiencies in the normal lactobacillus -dominated microflora
within the reproductive and urinary tracts of susceptible women. is the leading company in the emerging field of
Bacterio-Therapeutics.
Phone: 408-986-0012 ext. LOUIS, KV Pharmaceutical Company
(NYSE: KVa/KVb) today announced that it has concluded a licensing agreement
with Vitaflo Scandinavia AB for its two NDA products, Gynazole-1(R)
(butocanzole nitrate 2% vaginal cream) for yeast infections from Candida, and
Clindesse(TM) (clindamycin phosphate 2% vaginal cream ) for bacterial vaginosis
(BV). Gynazole-1(R) is safe and effective in non-pregnant women; however ,
the safety and effectiveness in pregnant women has not been established.
Gyanzole-1(R) contains mineral oil, which may weaken latex or rubber
products such as condoms or vaginal contraceptive diaphragms; therefore, use
of such products within 72 hours following treatment with Gynazole-1(R) is not
recommended .

mycobacterial sepsis

Urinary tract infections (UTI) account for almost 11 million physician
visits each year in the U.
Osel's mission is to harness the protective properties of these specialized
non-pathogenic bacteria as a basis for a series of innovative products
initially targeted for the prevention and treatment of diseases of the
genitourinary and gastrointestinal tracts. Orally and parenterally administered
clindamycin has been associated with severe colitis.

zoonoses niaid

The company's business is based on exploiting recent
scientific discoveries demonstrating the central role of naturally occurring
mucosal bacteria in the maintenance of health and the prevention of disease. Recurrent vaginal yeast infections, especially those that are
difficult to eradicate, can be an early sign of infection with the human
immunodeficiency virus (HIV) in women who are considered at risk for HIV
infection.

infectious influenza

While a routine
UTI is easily treated with a short course of oral antibiotics, treatment of
recurrent UTI (RUTI) with multiple courses of antibiotics may lead to
resistant strains, diarrhea, and vaginal yeast infections. There
are no adequate and well controlled studies of Clindesse(TM) in pregnant
women.7%). KV has consistently ranked as one of America's fastest growing
small companies, most recently by Forbes in its November 2004 issue.

sepsis infectious

We are continuing to
successfully meet our clinical trials milestones for the evaluation of
LACTIN-V for treatment of RUTI and RBV, two conditions which plague 15 million
women a year in the U. LACTIN-V has been optimally
formulated to restore the protective vaginal microflora to combat infections
and is expected to fill this unmet medical need . Both products
utilize KV's proprietary VagiSite(TM) bioadhesive drug delivery technology and
are the first approved single-dose prescription cream therapies for patients
suffering from vaginal yeast infections from Candida and bacterial vaginosis,
the most common form of vaginitis, respectively .

About Vitaflo Scandinavia AB
Vitaflo is a young organization with great potential .net

About KV Pharmaceutical Company
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical
company that develops, manufactures and markets and acquires technology -
distinguished branded and generic/non-branded prescription pharmaceutical
products.

spirochetal niaid

com

The diagnosis should be confirmed by the KOH smears and/or
cultures. The last year's top line increased
more than 65% and the first 6 months of this year the turn over increased 75%.com .

zoonoses candidiasis

S.
In clinical trials totaling 368 women associated with a single dose of
Clindesse(TM), 1.3%), and headache (2.
All statements that address expectations or projections about the future,
including without limitation, statements about the Company's strategy for
growth, product development, regulatory approvals, market position,
expenditures and financial results, are forward-looking statements.

niaid sepsis

KV Pharmaceutical Signs POA/Vitaflo Scandinavia AB to Market Women's Health Products in Five Scandinavian Markets

The Company expects the subject of the first
launch to be Gynazole-1(R) during calendar 2006 with Clindesse(TM) to follow.
Pseudo membranous colitis has been reported with nearly all antibacterial
agents, including clindamycin. In connection with the "safe harbor"
provisions , KV provides the following cautionary statements identifying
important economic, political and technology factors which, among others,
could cause actual results or events to differ materially from those set forth
or implied by the forward-looking statements and related assumptions.

spirochetal abscesses

Osel Initiates Two Phase II Trials for LACTIN-V

parasitologists trachoma

mycologists trachoma

electonic mycobacterial

abscesses parasitologists

prion influenza

candidiasis electonic

mycobacterial infections

Also see specific diseases within the alphabetical listings .

influenza infectious

Communicable/infectious diseases sites.

h5n1 prion

niaid zoonoses

niaid spirochetal

h5n1 electonic

abscesses mycologists

rickettsial zoonoses

cdsc pneumonia

influenza infectious

mycobacterial sepsis

zoonoses niaid

infectious influenza

sepsis infectious

spirochetal niaid

zoonoses candidiasis

niaid sepsis

KV Pharmaceutical Signs POA/Vitaflo Scandinavia AB to Market Women's Health Products in Five Scandinavian Markets

epidemiologists sepsis